Have your own idea? Try our Stock Screener
Taiwanese (TAIEX) Biotech Industry Analysis
UpdatedFeb 17, 2026
DataAggregated Company Financials
Companies70
- 7D-0.5%
- 3M27.4%
- 1Y1.9%
- YTD17.4%
Last week, the Biotech industry hasn't moved much but Elixiron Immunotherapeutics (Cayman) is up 25% in that time. In line with that, the industry has also been flat over the past 12 months. Looking forward, earnings are forecast to grow by 39% annually.
Industry Valuation and Performance
Has the Taiwanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 17 Feb 2026 | NT$683.1b | NT$33.4b | -NT$8,954,206,000.00 | 29.6x | -76.3x | 20.4x |
| Thu, 15 Jan 2026 | NT$593.9b | NT$33.4b | -NT$7,105,005,000.00 | 29.8x | -83.6x | 17.8x |
| Sat, 13 Dec 2025 | NT$569.5b | NT$33.4b | -NT$6,850,221,000.00 | 29.7x | -83.1x | 17.1x |
| Mon, 10 Nov 2025 | NT$524.4b | NT$33.4b | -NT$7,572,051,000.00 | 34.8x | -69.3x | 15.7x |
| Wed, 08 Oct 2025 | NT$560.5b | NT$32.2b | -NT$8,364,979,000.00 | 37.3x | -67x | 17.4x |
| Fri, 05 Sep 2025 | NT$533.2b | NT$32.2b | -NT$8,665,529,000.00 | 34.5x | -61.5x | 16.6x |
| Sun, 03 Aug 2025 | NT$501.7b | NT$30.7b | -NT$7,745,785,000.00 | 36x | -64.8x | 16.4x |
| Tue, 01 Jul 2025 | NT$513.2b | NT$30.2b | -NT$6,425,159,000.00 | 38.1x | -79.9x | 17x |
| Thu, 29 May 2025 | NT$498.3b | NT$30.1b | -NT$6,540,538,000.00 | 31.6x | -76.2x | 16.6x |
| Sat, 26 Apr 2025 | NT$473.9b | NT$28.5b | -NT$7,489,336,000.00 | 32.6x | -63.3x | 16.6x |
| Mon, 24 Mar 2025 | NT$539.8b | NT$28.1b | -NT$7,633,211,000.00 | 30.9x | -70.7x | 19.2x |
| Wed, 19 Feb 2025 | NT$607.0b | NT$24.8b | -NT$10,951,391,000.00 | 37.6x | -55.4x | 24.5x |
| Fri, 17 Jan 2025 | NT$549.9b | NT$24.8b | -NT$10,902,841,000.00 | 34.3x | -50.4x | 22.2x |
| Sun, 15 Dec 2024 | NT$503.1b | NT$24.8b | -NT$10,848,531,000.00 | 34.8x | -46.4x | 20.3x |
| Tue, 12 Nov 2024 | NT$538.6b | NT$23.5b | -NT$10,827,014,000.00 | 40.2x | -49.7x | 22.9x |
| Thu, 10 Oct 2024 | NT$532.3b | NT$23.5b | -NT$10,829,095,000.00 | 35.8x | -49.2x | 22.7x |
| Sat, 07 Sep 2024 | NT$564.0b | NT$23.5b | -NT$10,829,095,000.00 | 33.2x | -52.1x | 24x |
| Mon, 05 Aug 2024 | NT$552.4b | NT$22.0b | -NT$11,428,602,000.00 | 41.5x | -48.3x | 25.1x |
| Wed, 03 Jul 2024 | NT$556.2b | NT$21.9b | -NT$11,110,643,000.00 | 43.4x | -50.1x | 25.4x |
| Fri, 31 May 2024 | NT$493.4b | NT$21.9b | -NT$11,110,643,000.00 | 41.4x | -44.4x | 22.5x |
| Sun, 28 Apr 2024 | NT$436.0b | NT$21.1b | -NT$12,463,391,000.00 | 49.1x | -35x | 20.7x |
| Tue, 26 Mar 2024 | NT$436.3b | NT$20.9b | -NT$10,146,524,000.00 | 52.8x | -43x | 20.9x |
| Thu, 22 Feb 2024 | NT$449.6b | NT$19.9b | -NT$9,857,794,000.00 | 39.7x | -45.6x | 22.6x |
| Sat, 20 Jan 2024 | NT$449.8b | NT$19.8b | -NT$9,748,146,000.00 | 39.9x | -46.1x | 22.8x |
| Mon, 18 Dec 2023 | NT$474.3b | NT$19.9b | -NT$9,737,975,000.00 | 42.5x | -48.7x | 23.9x |
| Wed, 15 Nov 2023 | NT$465.9b | NT$19.0b | -NT$10,324,208,000.00 | 47x | -45.1x | 24.5x |
| Fri, 13 Oct 2023 | NT$467.2b | NT$18.3b | -NT$10,774,226,000.00 | 46.1x | -43.4x | 25.5x |
| Sun, 10 Sep 2023 | NT$487.9b | NT$18.3b | -NT$10,596,353,000.00 | 42.6x | -46x | 26.6x |
| Tue, 08 Aug 2023 | NT$467.8b | NT$18.6b | -NT$10,798,870,000.00 | 51.5x | -43.3x | 25.2x |
| Thu, 06 Jul 2023 | NT$486.0b | NT$18.7b | -NT$10,709,428,000.00 | 44x | -45.4x | 26x |
| Sat, 03 Jun 2023 | NT$493.7b | NT$18.8b | -NT$10,346,471,000.00 | 43.4x | -47.7x | 26.3x |
| Mon, 01 May 2023 | NT$515.7b | NT$18.5b | -NT$9,925,325,000.00 | 44.1x | -52x | 27.9x |
| Wed, 29 Mar 2023 | NT$500.8b | NT$20.5b | -NT$9,016,573,000.00 | 37.6x | -55.5x | 24.5x |
| Fri, 24 Feb 2023 | NT$527.8b | NT$21.8b | -NT$7,840,926,000.00 | 38x | -67.3x | 24.2x |
Price to Earnings Ratio
-67.3x
Current Industry PE
- Investors are relatively neutral on the Taiwanese Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 21.7x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 15% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Taiwanese Healthcare industry?
| TW Market | 3.43% | |
| Healthcare | -1.39% | |
| Biotech | -0.52% | |
| Biotech | -0.52% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 7871 Elixiron Immunotherapeutics (Cayman) | NT$63.10 | 12.7% +NT$953.4m | n/a | PS8258.2x | |
| 6550 Polaris Group | NT$29.90 | 2.2% +NT$500.8m | -38.6% | PS325.2x | |
| 7827 HanchorBio | NT$130.00 | 1.6% +NT$260.0m | n/a | PS54.1x | |
| 6712 Ever Supreme Bio Technology | NT$154.00 | 1.3% +NT$175.2m | -2.4% | PE25.9x | |
| 7832 Intelligene | NT$14.55 | 2.1% +NT$174.0m | n/a | PS2511.6x |